cis-Calamenene is a sesquiterpene hydrocarbon found in a range of woods, leaves, and specialty aromatic materials, including the archive's amber fossilized oil profile. The live evidence base is much stronger for identity, stereochemical naming, and repeated GC-MS occurrence than for isolated human-use pharmacology. Accessible bioactivity papers usually test whole oils or fractions that contain cis-calamenene among many co-constituents, so AromaForge should present it primarily as a chemistry and composition marker with cautious mixture-level context and explicit standalone evidence gaps.
Chemical identity and composition
PubChem's calamenene record groups cis-calamenene under a broader compound entry, while NIST provides a cis-specific WebBook page and CAS 72937-55-4 for the stereochemical isomer. Some databases and supplier pages also surface the older generic calamenene CAS 483-77-2, so preserving both search paths is useful. In the archive, cis-calamenene is currently linked directly to the amber fossilized Pinus succinifera distillate, where it is listed as a principal constituent without a disclosed percentage.
Aroma and practical use
- Use the recorded herbal, spicy, dry, woody, herbaceous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2006 Journal of Ethnopharmacology paper reported 1S,cis-calamenene at 13.1% in an active Cupressus lusitanica fraction with antidermatophytic activity.
The antifungal activity was measured at the fraction level, not with purified cis-calamenene alone, so the finding supports association rather than constituent attribution.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2012 Natural Product Communications paper identified cis-calamenene at 6.3% in Pogostemon travancoricus essential oil.
This is an occurrence finding rather than a pharmacology result, but it supports cis-calamenene as a repeated chemotaxonomic and composition marker in aromatic plants.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2012 Lebanese medicinal-plants paper reported cis-calamenene at 7.8% in Juniperus oxycedrus oil while testing whole-oil cytotoxicity against leukemia cell lines.
Because the biological assay used the whole oil, the result does not isolate cis-calamenene as the confirmed driver of the observed cytotoxicity.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
The Good Scents cis-calamenene page reviewed in this pass did not provide fragrance-use or flavor-use recommendations and showed no established cosmetic-use guidance.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No constituent-specific IFRA limit, dedicated human tolerability study, or phototoxicity warning for isolated cis-calamenene was verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Because public pharmacology evidence is mostly mixture-level, archive copy should avoid implying established effects for isolated cis-calamenene.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
no_constituent_specific_mechanism_verified
No direct mechanistic paper on isolated cis-calamenene was verified in this pass; the accessible literature mainly discusses it as part of active fractions or whole oils.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- No human clinical study specific to isolated cis-calamenene was verified in this pass.
- No purified-constituent mechanistic or dose-response paper for cis-calamenene was located in the accessible source set.
- Constituent-specific dermal, inhalation, and repeated-dose safety data for isolated cis-calamenene were not located.
- A c6 verification search (2026-07-13) found no RIFM/IFRA safety assessment or dermal-limit citation for cis-calamenene (CAS 72937-55-4); the prior unsourced 25% dermal_limit_pct and sensitizing:true were corrected to null.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.